Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachael Liu

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Contemporary Clinical Trials|July 14, 2020
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapyRachael Liu, Jianchang Lin, Pin Li
Pharmaceutical Statistics|December 14, 2022
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ETYunqi Zhao, Rachael Liu, Kentaro Takeda
Pharmaceutical Statistics|August 1, 2025
A Flexible Seamless Phase 2/3 Design With Biomarker-Driven Subgroup Enrichment and Sample Size Re-EstimationZizhong Tian, Liwen Wu, Rachael Liu, et al.
Statistics in Medicine|October 20, 2023
BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpointsDehua Bi, Meizi Liu, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|March 29, 2024
Flexible seamless 2-in-1 design with sample size adaptationRunjia Li, Liwen Wu, Rachael Liu, et al.
Contemporary Clinical Trials|September 17, 2020
Flexible Bayesian subgroup analysis in early and confirmatory trialsVeronica Bunn, Rachael Liu, Junjing Lin, et al.
Journal of Biopharmaceutical Statistics|September 21, 2020
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacyPin Li, Rachael Liu, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|August 24, 2022
PMED: Optimal Bayesian Platform Trial Design with Multiple EndpointsTian He, Rachael Liu, Meizi Liu, et al.
Statistics in Medicine|February 8, 2025
DOD-SSR: An Adaptive Seamless Phase II/III Design With Dose Optimization Decision and Sample Size Re-estimationMeizi Liu, Jianchang Lin, Yefei Zhang, et al.
Clinical Pharmacology and Therapeutics|July 10, 2020
Quantitative Translation in Immuno-Oncology Research and DevelopmentDean Bottino, Rachael Liu, Hojjat Bazzazi, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Contemporary Clinical Trials|July 14, 2020
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapyRachael Liu, Jianchang Lin, Pin Li
Pharmaceutical Statistics|December 14, 2022
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ETYunqi Zhao, Rachael Liu, Kentaro Takeda
Pharmaceutical Statistics|August 1, 2025
A Flexible Seamless Phase 2/3 Design With Biomarker-Driven Subgroup Enrichment and Sample Size Re-EstimationZizhong Tian, Liwen Wu, Rachael Liu, et al.
Statistics in Medicine|October 20, 2023
BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpointsDehua Bi, Meizi Liu, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|March 29, 2024
Flexible seamless 2-in-1 design with sample size adaptationRunjia Li, Liwen Wu, Rachael Liu, et al.
Contemporary Clinical Trials|September 17, 2020
Flexible Bayesian subgroup analysis in early and confirmatory trialsVeronica Bunn, Rachael Liu, Junjing Lin, et al.
Journal of Biopharmaceutical Statistics|September 21, 2020
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacyPin Li, Rachael Liu, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|August 24, 2022
PMED: Optimal Bayesian Platform Trial Design with Multiple EndpointsTian He, Rachael Liu, Meizi Liu, et al.
Statistics in Medicine|February 8, 2025
DOD-SSR: An Adaptive Seamless Phase II/III Design With Dose Optimization Decision and Sample Size Re-estimationMeizi Liu, Jianchang Lin, Yefei Zhang, et al.
Clinical Pharmacology and Therapeutics|July 10, 2020
Quantitative Translation in Immuno-Oncology Research and DevelopmentDean Bottino, Rachael Liu, Hojjat Bazzazi, et al.
Pageof 4